Introduction
WISP-1 is a member of the CCN family of growth factors (1-3) composed of WISP-1/Elm1, WISP-2/Cop1, WISP-3, CTGF (connective tissue growth factor), Cyr61 (cysteine-rich 61) and NOV (nephroblastoma overexpressed). WISP-1 was originally cloned based on its induced expression in the C57MG mouse mammary epithelial cell line transformed by the oncogene Wnt-1 (4). Although Wnt-1 is not present in the normal mammary gland, its expression in transgenic mice induces mammary tumors (5, 6) . Because its induction is associated with the expression of Wnt-1, WISP-1 is a putative downstream effector of the Wnt/Frizzled pathway (4) . Recently, WISP-1 was identified as a ß-catenin-regulated gene that might contribute to Wnt-1 mediated tumorigenesis (7) . Its link to tumorigenesis was also demonstrated by amplification of its genomic DNA and overexpression of its RNA in human colon tumors compared with patient matched normal mucosa (4) . WISP-1 is thought to act in an autocrine fashion because its overexpression in normal fibroblasts induces morphological transformation, accelerates cell growth, enhances saturation density and induces tumor formation in a xenograft mouse model (7) . The high level of expression in peritumoral stroma suggests that Full length mouse WISP-1 (Acc. Number: NM_018865) was cloned into an expression vector encoding the human IgG1 Fc region downstream of the WISP-1 sequence as described previously for tumor necrosis factor receptor 1 (TNFR-1) (19) . The resulting recombinant fusion protein (WISP-1-Fc) was synthesized in a baculovirus expression system using Sf9 insect cells and purified to homogeneity from serum-free conditioned medium by affinity chromatography on a protein A-Sepharose 4 Fast Flow (Pharmacia Biotech, Sweden) column. Unadsorbed proteins were washed out with 50 mM sodium phosphate buffer containing 1 M NaCl. WISP-1-Fc was eluted with 100 mM glycine pH 2.5 and the pH was neutralized with 0.1 volume of 3 M Tris-HCl pH 8. After dialysis (20 mM Tris-HCl pH 7.5, 150 mM) the purified protein was concentrated by ultrafiltration using centriprep-30 (Millipore corp., Bedford MA) and the purity estimated by SDS-PAGE and silver staining. Monoclonal anti-WISP-1 antibodies were generated using the WISP-1-Fc fusion protein as antigen. The antibody was raised in mouse and purified by affinity chromatography on a protein A agarose column. The experiments described were repeated at least three times with three different batches of protein expressed and purified at different times and similar results were obtained. Treatment of Cell Surface Proteoglycan with Glycosaminoglycan Lyases-Conditions for the use of glycosaminoglycan lyases were as previously described with modifications (20) . Briefly, where indicated, cells were washed and incubated 2 h at 37°C with 0.1 U of the different lyases.
The cells were then washed twice with HBS-C and used for binding.
Cell Binding-Cells (8-10 X 10
3 ) were plated in 8 well plastic chamber slides and maintained overnight at 37 °C, 5% CO2. The next day the cells were washed with PBS and the non-specific binding sites were saturated for 30 min at room temperature with HBS-C/3 % BSA. The cells were incubated with 1 nM WISP-1-Fc for 1 h at room temperature, washed and incubated with 0.2 µg/ml biotinylated anti-human IgG Fc' in HBS-C/3% BSA for 30 min at room temperature.
The signal was amplified using the TSA indirect kit according to the manufacturer instructions.
After a 30 minute incubation with 1:200 FITC conjugated streptavidin, the slides were mounted using Vectashield containing 1 µg/ml Hoechst 33342 and visualized under a Nikon Eclipse 800 fluorescent microscope. Images were acquired with a Photometrics 300 CCD camera operated at -40°C interfaced with an Apple G3 computer and the Metamorph imaging software from Universal Imaging Corporation (Downingtown, PA). Measurement of the fluorescence intensity of cells was as previously described with modifications (21) . Briefly, images of a minimum of three separate fields containing an average of 90 cells were acquired and stored as electronic files. The threshold was defined as the lowest intensity of the 1% brightest pixels in a negative control executed without WISP-1-Fc. The fluorescence signal for a cell population was defined as the total pixel intensity over the threshold divided by the cell number.
Solid Phase Binding Assay-Proteins were diluted in PBS (total volume 50 µl), applied to polystyrene microtiter wells and incubated at 4° C overnight. The next day the wells were washed three times with 300 µl of HBS-C/0.3% BSA and the non specific binding sites were blocked for 1 h at room temperature with 200 µl HBS-C/3% BSA. The buffer was aspirated and 50 µl of 0.5 nM WISP-1-Fc in HBS-C/3% BSA was incubated for 2 h at room temperature. The wells were washed and incubated for 1 h with 50 µl of 2 µg/ml horseradish peroxidase conjugated goat anti-human IgG Fc' in HBS-C/3%. At the end of the incubation, the wells were washed 6 times with 200 µl of PBS containing 0.05% Tween-20 and the signal was visualized using 100 µl of the horseradish peroxidase chromogenic substrate TMB (KPL). The reaction was stopped with 100 µl of 1 M phosphoric acid and the OD at 450 nm was measured. Non-specific WISP-1-Fc binding was determined in parallel incubations by omitting microtiter well coating.
No signal was generated when WISP-1-Fc was omitted or replaced by an irrelevant Fc fusion protein, TNFR1-Fc.
Purification of WISP-1 Binding Factors-Human skin fibroblasts were cycled between serum containing and serum free culture media every three days. The serum free conditioned media was concentrated using a centriprep-30 (Millipore, Bedford MA). The buffer was then changed by sequentially adding 20 mM Tris-HCl, pH 7.4, 300 mM NaCl and reconcentrating. The concentrate (150 µg protein/ml) was snap frozen and stored at -80 °C until used. The concentrated conditioned media was thawed, filtered and applied on a Mono Q anion exchange column equilibrated in 20 mM Tris-HCl, pH 7.4, containing 300 mM NaCl. The column was washed and the adsorbed proteins were eluted using a linear gradient of NaCl (300 mM -2 M) in the same buffer. Fractions of 500 µl were analyzed for WISP-1 binding activity.
Protein Identification by Mass Spectrometry-
The fractions containing the WISP-1 binding activity were pooled, denatured, reduced and applied to a 4-15% gradient SDS poly-acrylamide gel with or without a previous incubation for 2 h at 37° C with 0.1 U of chondroitinase ABC.
The gels were silver stained and the protein bands demonstrating a mobility change upon chondroitinase ABC digestion were excised and digested in situ with trypsin as previously described (22) . Tryptic peptides were extracted and analyzed by microcapillary reverse-phase liquid chromatography-mass spectrometry. Peptide mixtures were loaded onto 100 µm i. Analytical Methods-SDS-PAGE was performed as described (24) using a Bio-Rad Mini-PROTEAN II vertical slab gel electrophoresis apparatus and the proteins were stained using the Silver stain plus kit from Bio-Rad. The apparent molecular mass was determined using the broad range molecular weight standards from Bio-Rad. Protein was determined using the Bio-Rad Protein Assay Dye Reagent and bovine serum albumin standard. To characterize the nature of the interaction, the assay was performed under various conditions. The binding was abolished by 1 M NaCl, reduced by 25% with 100 mM EDTA while 0.05% Tween-20 had no effect ( 
Results

WISP-1 Binds to Human Colon Tumor Stroma
WISP-1 Binds to Human Skin Fibroblast Conditioned Media-
WISP-1 Binds To Decorin and Biglycan -We assessed the interaction of WISP-1 with
decorin and biglycan using a solid phase assay. WISP-1 specific binding was identical for both proteins and proportional to the amount of protein coated (Fig. 7A) . Similarly, WISP-1 interaction with human skin fibroblast conditioned media was gradually decreased in the presence of increasing concentrations of decorin or biglycan (Fig. 7B) . Competition curves gave an IC 50 of 70 µg/ml for decorin and 105 µg/ml for biglycan. Dissociation constants were measured using saturation curves ( Fig. 7 C and D (Fig. 8D ), diminished the interaction by 60-70% (Fig. 8E ). On the other hand, the presence of dermatan sulfate completely abolished WISP-1 binding ( Fig. 8B & E) rendering the level of fluorescence comparable to a negative control executed in absence of WISP-1 (data not shown). The relative level at which the different glycosaminoglycans reduced WISP-1 interaction with the cell surface paralleled their efficiency at competing the binding to human skin fibroblast conditioned media (Fig 6) . These results suggest that WISP-1 dermatan sulfate binding domains may be responsible for its interaction with the cell surface.
WISP-1 Binds to Cell Surface Dermatan Sulfate
Proteoglycan -To determine the role of glycosaminoglycans in WISP-1's interaction with the cell surface we analyzed its binding to glycosaminoglycan lyase treated human skin fibroblasts. Chondroitinase C or heparinase treatment marginally altered WISP-1 cell surface binding (Fig. 9A & D) . On the other hand, cells treated with chondroitinase ABC or chondroitinase B failed to bind WISP-1 (Fig. 9B & C) .
Digestion with various glycolytic enzymes altered the interaction with the cell surface and the conditioned media in a similar fashion ( Fig. 9 and Fig. 4 ). These results indicate that WISP-1 cell surface binding is mediated by dermatan sulfate proteoglycan.
WISP-1 Binds to Decorin at the Surface of Human Skin Fibroblasts-
The presence of decorin at the surface of human skin fibroblasts was assessed by immunofluorescence. Although decorin is a secreted proteoglycan, the fluorescent staining demonstrated that it covered a large portion of the human skin fibroblast surface (Fig. 10A ). This distribution paralleled the WISP-1 binding pattern (Fig. 10B ). In addition, WISP-1 interaction was diminished by 88% and 94% in the presence of decorin (Fig. 10C & D) or biglycan (Fig. 10D) . These results show that decorin and biglycan act as WISP-1 binding factors that can mediate and modulate its interaction with the cell surface. Using immunofluorescence, we confirmed the presence of decorin at the surface of the human skin fibroblasts. This is consistent with the predominant expression of decorin in mesenchymal cells (35, 36) . We also demonstrated that decorin and biglycan significantly diminished WISP-1 interaction. These results suggest that decorin and biglycan act as WISP-1 binding factors that can mediate and modulate its interaction with the cell surface. Although decorin and biglycan appear to be the major binding factors, we can not exclude WISP-1 interaction with other proteoglycans.
Other members of the CCN family including Cyr61 (11) CTGF (26) residues was shown to alter the specificity of glycosaminoglycan binding in many proteins (37) .
Although several types of glycosaminoglycan binding domains have been described, the specific glycosaminoglycan sequences described to date contain at least one iduronate residue (37) . The conformational flexibility of this residue may play an important role in the binding to proteins (38) . Alternatively, the dermatan sulfate binding might be mediated by a motif of WISP-1 outside of the carboxy-terminal domain.
All members of the CCN family contain one copy of the thrombospondin type I repeat (39) . A similar domain is also found in several extracellular proteins including malaria circumsporozoite protein, TRAP, F-spondin, complement 6, ADAMTS-1, semaphorin and properdin (1). The consensus region includes the WSxCSxxCG motif and six conserved cysteines and covers about 60 residues (1). This motif is though to be involved in binding to sulfated glycoconjugates (8) The expression of decorin correlates with malignancy in human carcinomas (44, 45) .
Decorin is reduced in many tumor types (46) , absent in several tumor cell lines (47) , but increased in the tumor stroma (46, 48, 49) . Since decorin was shown to directly suppress the growth of several carcinomas, its expression in the peritumorous stroma may reflect a regional response of the host connective tissue cells to the invading neoplastic cells (50, 51) . 
